Cite
PD-L1 as the Prognostic Immune Biomarker for Predicting the Relapse of Locally Advanced Cervical Adenocarcinoma and Adenosquamous Carcinoma Treated with Definitive Chemoradiation Therapy.
MLA
Lai, Y. L., et al. “PD-L1 as the Prognostic Immune Biomarker for Predicting the Relapse of Locally Advanced Cervical Adenocarcinoma and Adenosquamous Carcinoma Treated with Definitive Chemoradiation Therapy.” International Journal of Radiation Oncology, Biology, Physics, vol. 99, Oct. 2017, pp. E299–300. EBSCOhost, https://doi.org/10.1016/j.ijrobp.2017.06.1318.
APA
Lai, Y. L., Chen, L. C., Huang, C. Y., Chiang, S. F., Liang, J. A., Chao, K. S. C., & Chen, S. W. (2017). PD-L1 as the Prognostic Immune Biomarker for Predicting the Relapse of Locally Advanced Cervical Adenocarcinoma and Adenosquamous Carcinoma Treated with Definitive Chemoradiation Therapy. International Journal of Radiation Oncology, Biology, Physics, 99, E299–E300. https://doi.org/10.1016/j.ijrobp.2017.06.1318
Chicago
Lai, Y.L., L.C. Chen, C.Y. Huang, S.F. Chiang, J.A. Liang, K.S.C. Chao, and S.W. Chen. 2017. “PD-L1 as the Prognostic Immune Biomarker for Predicting the Relapse of Locally Advanced Cervical Adenocarcinoma and Adenosquamous Carcinoma Treated with Definitive Chemoradiation Therapy.” International Journal of Radiation Oncology, Biology, Physics 99 (October): E299–300. doi:10.1016/j.ijrobp.2017.06.1318.